Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like Why the Best is Yet to Come for This Tiny Massachusetts Biotech November 27, 2017 2 Biotechs That Had a Rough 2016 But May Be Poised for a Turnaround This Year February 22, 2017 Despite Spike, Why Investors Should Still Avoid MannKind Like the Plague January 30, 2018
